TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03776747

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Supine hyperpolarized 3 helium gas scan
Description: Hyperpolarized gas used as a contrast agent to test reproducibility of MRI of the lungs/Images done while subject is supine.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Vitals

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Vitals

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Pulmonary Function Tests
Description: Pre and post spirometry, diffuse lung carbon monoxide (DLCO), lung volumes

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary Function Tests
Description: Pre and post spirometry, diffuse lung carbon monoxide (DLCO), lung volumes

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Initial protocol MRI scan
Description: Initial scan to determine placement

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Initial protocol MRI scan
Description: Initial scan to determine placement
Study: NCT03373149

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Growth hormone/HPuFSH/GnRH antagonist
Description: Growth hormone (Somatropin, Sedico, Egypt) \[4 IU/day\] and highly purified urinary FSH (HPuFSH) (Fostimon,IBSA, Switzerland) \[300 IU/day\] will be started on cycle day 3 and will be continued until and including the day of human chorionic gonadotropin (HCG) administration. Starting from cycle day 8, the dose of HPuFSH will be adjusted individually according to ovarian response which will be monitored using transvaginal ultrasound and serum estradiol (E2).~GnRH antagonist (Cetrorelix acetate) (Cetrotide; Serono International S.A., Geneva, Switzerland) 0.25 mg S.C. once daily will be started when the leading follicle is 14 mm in mean diameter and will be continued until and including the day of HCG administration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HPuFSH/GnRH antagonist
Description: Highly purified urinary FSH (HPuFSH) (Fostimon,IBSA, Switzerland) \[300 IU/day\] will be started on cycle day 3 and will be continued until and including the day of human chorionic gonadotropin (HCG) administration. Starting from cycle day 8, the dose of HPuFSH will be adjusted individually according to ovarian response which will be monitored using transvaginal ultrasound and serum estradiol (E2).~GnRH antagonist (Cetrorelix acetate) (Cetrotide; Serono International S.A., Geneva, Switzerland) 0.25 mg S.C. once daily will be started when the leading follicle is 14 mm in mean diameter and will be continued until and including the day of HCG administration.
Study: NCT03594682

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention/treatment
Description: experimentalgroup initial dose：~1. 250mg qod~2. 250mg qd/500mg qd by turn~3. 500mg qd control group： 750mg qd

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intervention/treatment
Description: experimentalgroup initial dose：~1. 250mg qod~2. 250mg qd/500mg qd by turn~3. 500mg qd control group： 750mg qd
Study: NCT00763386

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NexGen LPS-Flex Fixed Bearing Knee
Description: NexGen LPS-Flex Fixed Bearing femoral component
Study: NCT00732589

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1% xylocaine
Description: 10 cc. of 1%xylocaine, once a week
Study: NCT00763386

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NexGen Legacy Posterior Stabilized Knee
Description: NexGen Legacy Posterior Stabilized femoral component
Study: NCT03567031

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EtCO2 modification
Description: Controlled modification of EtCO2 through modification of ventilation parameters under general anesthesia without spontaneous breathing
Study: NCT00732589

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ultrasound
Description: ultrasound at shoulder area about 10 mins.
Study: NCT01696669

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: * Vincristine, 2 mg/m\^2 IV bolus, day 1.~* Doxorubicin: 75 mg/m\^2 per cycle, or 25 mg/m\^2/day x 3 days, IV infusion, 1 hour (after dexrazoxane administration at the dose of 10:1).~* Dexrazoxane: administered at a dose of 10:1, before doxorubicin only in adults.~* Cyclophosphamide: 2100 mg/m\^2 IV infusion, 6 hours, with MESNA protection, days 1 and 2.~* MESNA: used with cyclophosphamide and ifosfamide. The total daily dose of MESNA is equivalent to at least 60% of the daily dose of cyclophosphamide or ifosfamide.~* G-CSF: 5 micrograms/kg/day SC. It starts 24 hours after the last dose of chemotherapy and continues until the absolute neutrophil count is ≥ 750 mm\^3/L.~* Ifosfamide: 1800 mg/m\^2/day IV infusion, 1 hour, days 1-5 of each cycle (9,000 mg/m\^2 total maximum dose).~Window phase in high-risk patients (21-days cycle):~* Gemcitabine: 1000 mg/m\^2 IV, 90 minutes on day 1 and 8.~* Docetaxel 100 mg/m\^2, 2-3 hour infusion on day 8.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Surgical intervention aiming to completely resect the tumor with negative margins.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: On the primary tumor bed in case of unresectable tumors, resected tumors with inadequate margins, or those with histologic response \<90%. Patients will receive radiotherapy 21 days after the completion of chemotherapy.
Study: NCT05851833

Intervention type: BEHAVIORAL
Intervention: Early Mobilization
Description: The time the patient began to sit, stand, and walk after surgery is earlier than traditional model.
Study: NCT01757314

Intervention type: BEHAVIORAL
Intervention: ultrasound technique
Description: instruction in the ultrasound technique

Intervention type: OTHER
Intervention: palpation technique
Description: placement of a line via palpation technique
Study: NCT02669342

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Radiance™ Clear Sharklet® Silicone Foley Catheter
Study: NCT02461329

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gelofusine® B. Braun
Description: Volume therapy by Gelatine solution infusion via intravenous boluses to achieve hemodynamic targets
Study: NCT02445469

Intervention type: OTHER
Group type: OTHER
Intervention: MRI exam of the brain
Description: MRI exam of the brain
Study: NCT03276208

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prenatal Massage
Description: We will utilize moderate pressure Swedish massage (SM) that utilizes long slow strokes known as effleurage and kneading strokes known as petrissage. A specific routine will be performed on each participant with focus on low back, upper back, shoulders, and neck musculature. Consistent moderate pressure, which is lighter than deep tissue massage but deeper than brush strokes, will be used.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mindfulness
Description: The intervention and control group will be enrolled in the Craving to Quit® program, a 21-day mindfulness-based program delivered via a smartphone application (https://www.cravingtoquit.com/). This program uses a mindfulness-based approach to train people to recognize and be aware of their tobacco cravings. The program includes videos, online exercises to complete, and a virtual support community.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness
Description: The intervention and control group will be enrolled in the Craving to Quit® program, a 21-day mindfulness-based program delivered via a smartphone application (https://www.cravingtoquit.com/). This program uses a mindfulness-based approach to train people to recognize and be aware of their tobacco cravings. The program includes videos, online exercises to complete, and a virtual support community.
Study: NCT02360332

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Project SEARCH plus ASD Supports
Description: Project SEARCH program (Rutkowski, Daston, Kuiken, and Riehle, 2006) is a work based learning model for high school transition that was developed at Cincinnati Children's Hospital Medical Center. The model provides complete immersion in the workplace. Students spend their entire school day at the workplace for a full school year. Consistent with principles of work based learning, Project SEARCH facilitates the development of a broad range of high-quality jobs within the employer organization and provides over 700 of supervised work experience. The model also relies on the intensive application of supported employments strategies (task analysis and customization, systematic instruction, ongoing support, etc.) to allow the participation of individuals with extensive support needs.
Study: NCT01272206

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC 0128-0000-2011
Description: Administered as one single i.v. (intravenous) injection, 100 mcg/kg
Study: NCT02461329

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ringerfundin ® B. Braun
Description: Volume therapy by Balanced Crystaloid solution solution infusion via intravenous boluses to achieve hemodynamic targets
Study: NCT01272206

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC 0128-0000-2021
Description: Administered as one single i.v. (intravenous) injection, 100 mcg/kg
Study: NCT04676204

Intervention type: DRUG
Intervention: Cladribine
Description: Cladribine is a purine antimetabolite indicated for the treatment of relapsing forms of multiple sclerosis, to include relapsing-remitting disease and active secondary progressive disease, in adults.

Intervention type: DRUG
Intervention: Dimethyl fumarate
Description: Dimethyl fumarate is indicated for the treatment of relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults

Intervention type: DRUG
Intervention: Fingolimod
Description: Fingolimod is a sphingosine 1-phosphate receptor modulator indicated for the treatment of patients with relapsing forms of multiple sclerosis to reduce the frequency of clinical exacerbations and to delay the accumulation of physical disability.

Intervention type: DRUG
Intervention: Teriflunomide
Description: Teriflunomide is a pyrimidine synthesis inhibitor indicated for the treatment of patients with relapsing forms of multiple sclerosis.

Intervention type: DRUG
Intervention: Ozanimod
Description: Ozanimod is a sphingosine-1-phosphate receptor modulator indicated for the treatment of patients with relapsing forms of multiple sclerosis.

Intervention type: DRUG
Intervention: Diroximel fumarate
Description: Diroximel fumarate is indicated for the treatment of relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
Study: NCT03897335

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aminophylline
Description: Aminophylline pre cardiopulmonary bypass and immediately post cardiopulmonary bypass. The dose will be Aminophylline 5 mg/kg/dose, max 350 mg slow infusion. The infusion rate duration will be standardized to 20 minutes. There will be no other aminophylline treatments for the first post-op five days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo group will not receive any aminophylline treatments for the first post-op five days
Study: NCT05189002

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dimolegin 40 mg
Description: Dimolegin - DD217 - 40 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dimolegin 60 mg
Description: Dimolegin - DD217 - 60 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fragmin
Description: Fragmin 5000 IU in 0.2 ML Prefilled Syringe
Study: NCT00587665

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketamine
Description: Single IV dose of 0.1 mg/kg of ketamine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline given of equal volume to drug
Study: NCT02199574

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EXPAREL
Description: 133 mg EXPAREL in 10 mL.
Study: NCT00891813

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zemplar (paricalcitol)
Description: Zemplar (paricalcitol) dose will be calculated mcg=PARATHYROID HORMONE level/100; this will be provided 3 times per week. Dose will be adjusted by 2-4 mcg every 4 weeks according to the parathyroid hormone level.
Study: NCT00255580

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Smoked cannabis

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Smoked cannabis
Study: NCT01491516

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TELAMON P™ /INFUSE® Bone Graft/CD HORIZON® Spinal System
Description: The TELAMON P™/INFUSE™ Bone Graft Implant in conjunction with the CD HORIZON® Spinal System for single level lumbar fusion from L1 to S1
Study: NCT04221971

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chemotherapy combined with NK cells infusion
Description: chemotherapy combined with NK cells infusion
Study: NCT02669342

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Radiance™ Clear Sharklet® Silicone Foley Catheter

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Silicone Foley Catheter

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Silicone Foley Catheter
Study: NCT00381004

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Course 1: 250 mg/m\^2 by vein over 5-30 minutes on Days 2, 3, and 4; Course 2 - 6: 250 mg/m\^2 by vein over 5-30 minutes on Days 1 - 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Course 1: 25 mg/m\^2 by vein over 5-30 minutes on Days 2,3, and 4; Course 2 - 6: 25 mg/m\^2 by vein over 5-30 minutes on Days 1 - 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sargramostim
Description: Course 1: 250 mcg/m\^2 subcutaneous (SQ) on Days -1 and Days 5 - 11; Course 2 - 6: 250 mcg/m\^2 SQ on Days -1 and Days 4 - 10

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Course 1: 375 mg/m\^2 by vein over 2-6 Hours on Day 1; Course 2 - 6: 500 mg/m\^2 by vein over 2-6 Hours on Day 1
Study: NCT00062179

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: carboplatin
Description: Carboplatin: dosed at an AUC of 6 by the Calvert Formula 3 cycles of carboplatin 21 days apart

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Carboplatin: dosed at an AUC of 6 by the Calvert Formula 3 cycles of carboplatin 21 days apart
Study: NCT01622114

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Evaluation of the Association between the Menstrual Cycle and Weight Loss in Healthy, Overweight Premenopausal Women
Description: 2-arm parallel 6 month study with the obejective to examine the impact of the menstrual cycle on weight loss attempts in healthy overweight premenopausal women randomized to two different weight management programs. The women may not use hormonal contraceptive agents other than an IUD.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Evaluation of the Association between the Menstrual Cycle and Weight Loss in Healthy, Overweight Premenopausal Women
Description: 2-arm parallel 6 month study with the obejective to examine the impact of the menstrual cycle on weight loss attempts in healthy overweight premenopausal women randomized to two different weight management programs. The women may not use hormonal contraceptive agents other than an IUD.
Study: NCT04289168

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music
Description: Music class was provided for the intervention group
Study: NCT02217579

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein
Description: A food containing 5 grams/serving of supplemental protein.
Study: NCT02471339

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Description: Acceptance and Commitment Therapy (ACT), a newer generation of cognitive-behavioral therapy, focuses on encouraging individuals to engage in more adaptive ways of coping with pain.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Acceptance and Commitment Therapy (ACT)
Description: Acceptance and Commitment Therapy (ACT), a newer generation of cognitive-behavioral therapy, focuses on encouraging individuals to engage in more adaptive ways of coping with pain.
Study: NCT02340455

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin_male
Description: Pregabalin 150mg bid 1day Men

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin_female
Description: Pregabalin 150mg bid 1day Women

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo_Men
Description: Placebo durg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo_Women
Description: Placebo_Women
Study: NCT04035616

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: microbial cell preparation [MCP]
Description: active microbial cell preparation

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: inactive ingredient
Study: NCT04075448

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: 100 grams breakfast cereal

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: 100 grams breakfast cereal

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 50 g Walnut
Description: 50 grams walnuts mixed with 50 gram breakfast cereal.
Study: NCT02217579

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Prebiotic fiber
Description: A food containing 8 grams/serving of supplemental prebiotic fiber.
Study: NCT04075448

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 50 g Walnut
Description: 50 grams walnuts mixed with 50 gram breakfast cereal.
Study: NCT04925635

Intervention type: BEHAVIORAL
Intervention: experimental group
Description: The arteriovenous fistula care mobile health application will be installed and promoted on the smart phones of the patients in the experimental group. Arteriovenous fistula care mobile health application will be installed in daytime groups during working hours during or at the end of dialysis according to the patient's request. In addition, the information contained in the arteriovenous care mobile health application will be verbally explained to the patients and their relatives, as well as shown in practice. The training results were evaluated by the researcher in the 1st and 3rd months in the Scale for Evaluation of Self-Care Behaviors Related to Arteriovenous Fistula in Hemodialysis Patients, Final Level of Renal Failure Compliance Scale, Arteriovenous Fistula Care Education Knowledge Level Evaluation Form (Post-Training Section) and  Visual Benchmarking Scale .

Intervention type: BEHAVIORAL
Intervention: control group
Description: Patients in the control group will receive arteriovenous fistula care training and a training booklet will be given. The information contained in the booklet will be explained orally to the patients and their relatives by the researcher, and will also be shown in practice. The results of the training were determined by the researcher at the 1st and 3rd months of the Self-Care Behaviors Scale for Arteriovenous Fistula in Hemodialysis Patients, End Stage Renal Failure Compliance Scale, Arteriovenous Fistula Care Training Information Level Assessment Form (Post-training section) and Visual It will be evaluated with the Comparison Scale.
Study: NCT02530385

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Capsules
Description: Placebo capsules contain powdered cocoa and gelatin

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FMT Capsules
Description: Capsules will be generated as per FDA-approved procedures
Study: NCT02217579

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein plus prebiotic fiber
Description: A food containing supplemental protein (5 grams/serving) and prebiotic fiber (8 grams/serving).

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: An isocaloric food not containing the test protein and fiber.
Study: NCT00143676

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapaquistat acetate and atorvastatin
Description: Lapaquistat acetate 50 mg, tablets, orally, once daily and Atorvastatin 10 mg to 40 mg stable dose for up to 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapaquistat acetate and atorvastatin
Description: Lapaquistat acetate 100 mg, tablets, orally, once daily and Atorvastatin 10 mg to 40 mg stable dose for up to 24 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: Lapaquistat acetate placebo-matching tablets, orally, once daily and Atorvastatin 10 mg to 40 mg stable dose for up to 24 weeks.
Study: NCT02092688

Intervention type: DEVICE
Intervention: novel kit for the detection of PAMG-1
Description: The novel kit for the detection of PAMG-1 is a diagnostic device employing monoclonal antibodies that detect Placental α1 Microglobulin present in cervico-vaginal secretions manufactured by AmniSure® International, LLC, Boston, MA. The in vivo sensitivity detection threshold is 4ng/ml. During the test procedure, PAMG-1 from the sample sequentially binds to monoclonal antibody conjugated with labeled particles, then to monoclonal antibody immobilized on an insoluble carrier. The test requires a 30 second swab saturation in the vagina (a sterile speculum examination is not required), a 30 second active washing step whereby the swab just removed from the vagina is actively rotated in a solvent filled vial and lastly, a 5 minute waiting period from the time the swab is removed and the test strip is inserted if two testing lines do not appear sooner.

Intervention type: DEVICE
Intervention: novel kit for the detection of PAMG-1
Description: The novel kit for the detection of PAMG-1 is a diagnostic device employing monoclonal antibodies that detect Placental α1 Microglobulin present in cervico-vaginal secretions manufactured by AmniSure® International, LLC, Boston, MA. The in vivo sensitivity detection threshold is 4ng/ml. During the test procedure, PAMG-1 from the sample sequentially binds to monoclonal antibody conjugated with labeled particles, then to monoclonal antibody immobilized on an insoluble carrier. The test requires a 30 second swab saturation in the vagina (a sterile speculum examination is not required), a 30 second active washing step whereby the swab just removed from the vagina is actively rotated in a solvent filled vial and lastly, a 5 minute waiting period from the time the swab is removed and the test strip is inserted if two testing lines do not appear sooner.
Study: NCT05028907

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5 mg chloramphenicol, 1 mg dexamethasone sodium phosphate, 0.25 mg tetryzoline hydrochloride, 2 mg Hydroxypropyl Methyl Cellulose, 10 mg α-tocopherol acetate and 8 mg macrogol 400).
Description: The patients were advised to apply the drops 5 times daily for the first week, three times daily for the next two weeks and one time daily for another one week. The patients were examined before treatment, one week, one month and three months later.